NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

Search

Himax Technologies Inc ADR

Suletud

8.68 1.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.53

Max

8.87

Põhinäitajad

By Trading Economics

Sissetulek

5M

6.3M

Müük

3.9M

203M

P/E

Sektori keskmine

38.24

77.27

Aktsiakasum

0.036

Dividenditootlus

3.87

Kasumimarginaal

3.12

Töötajad

2,200

EBITDA

6.9M

14M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+4.77% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.87%

2.29%

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

322M

1.7B

Eelmine avamishind

7.4

Eelmine sulgemishind

8.68

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Himax Technologies Inc ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk
Tulu
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Himax Technologies Inc ADR Prognoos

Hinnasiht

By TipRanks

4.77% tõus

12 kuu keskmine prognoos

Keskmine 9 USD  4.77%

Kõrge 10 USD

Madal 8 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Himax Technologies Inc ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

7.113 / 7.59Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Himax Technologies Inc ADR

Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies in China, Taiwan, the Philippines, Korea, Japan, Europe, and the United States. The company operates in two segments, Driver IC and Non-Driver Products. It offers display driver integrated circuits (ICs) and timing controllers that are used in televisions, PC monitors, laptops, mobile phones, tablets, automotive, ePaper devices, industrial displays, and other products. The company also provides automotive IC solutions, including traditional driver ICs; advanced in-cell touch and display driver integration; large touch and display driver integration; and local dimming timing controllers, as well as active matrix organic light-emitting diode (AMOLED) solutions, including AMOLED drivers, timing controllers, and touch controller ICs. In addition, it offers application specific IC services; liquid crystal on silicon and micro-electro mechanical system products; Power ICs; complementary metal oxide semiconductor image sensor products; wafer level optics products; 3D sensing products; and ultralow power WiseEye smart image sensing products. The company markets its display drivers to panel manufacturers, mobile device module manufacturers, and manufacturers of end-use products. Himax Technologies, Inc. was incorporated in 2001 and is headquartered in Tainan City, Taiwan.
help-icon Live chat